Eli Lilly to acquire cancer drug developer

Eli Lilly has revealed plans to acquire Montreal-based AurKa Pharma, in what is the company’s second acquisition in less than one week.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Eli Lilly to purchase Loxo Oncology for $8bn

7 January 2019 American pharmaceutical firm Eli Lilly and Company has announced a deal to acquire Loxo Oncology in a $8 billion deal.

Big Pharma

AbbVie in immuno-oncology agreement with biotech

23 August 2018 Pharmaceutical company AbbVie has signed an exclusive licensing agreement with biotech group Argenx to develop and commercialise immuno-oncology antibody ARGX-115.

Americas

Eli Lilly to buy immuno-oncology firm in $1.6bn deal

11 May 2018 Eli Lilly has set its sights on Armo BioSciences in a bid to strengthen its immuno-oncology programme.

More on this story

Americas

Eli Lilly to purchase Loxo Oncology for $8bn

7 January 2019 American pharmaceutical firm Eli Lilly and Company has announced a deal to acquire Loxo Oncology in a $8 billion deal.

Big Pharma

AbbVie in immuno-oncology agreement with biotech

23 August 2018 Pharmaceutical company AbbVie has signed an exclusive licensing agreement with biotech group Argenx to develop and commercialise immuno-oncology antibody ARGX-115.

Americas

Eli Lilly to buy immuno-oncology firm in $1.6bn deal

11 May 2018 Eli Lilly has set its sights on Armo BioSciences in a bid to strengthen its immuno-oncology programme.

More on this story

Americas

Eli Lilly to purchase Loxo Oncology for $8bn

7 January 2019 American pharmaceutical firm Eli Lilly and Company has announced a deal to acquire Loxo Oncology in a $8 billion deal.

Big Pharma

AbbVie in immuno-oncology agreement with biotech

23 August 2018 Pharmaceutical company AbbVie has signed an exclusive licensing agreement with biotech group Argenx to develop and commercialise immuno-oncology antibody ARGX-115.

Americas

Eli Lilly to buy immuno-oncology firm in $1.6bn deal

11 May 2018 Eli Lilly has set its sights on Armo BioSciences in a bid to strengthen its immuno-oncology programme.